Simultaneous Publication CRT 2026
Mar 10
David E Kandzari, Felix Mahfoud, et al.
This study evaluated 36-month blood pressure changes after RF-RDN across four clinical studies from the Symplicity program. Blood pressure reductions were significant with few adverse events, suggesting long-term safety and efficacy across a broad spectrum of patients with uncontrolled hypertension.
open access
Expert Review
Mar 9
Isa Bijloo, Yolande Appelman, et al.
This review examines the diagnostic modalities for coronary dysfunction in patients with angina and non-obstructive coronary artery disease, finding that only coronary flow reserve can be reliably measured non-invasively, while invasive coronary function testing remains the gold standard.
free
Viewpoint
Mar 6
Alfonso Jurado-Román, Mattia Basile
This article describes the use of excimer laser coronary atherectomy (ELCA) to modify atherosclerotic plaques, highlighting the evolution from infrared to excimer laser technology and the importance of procedural experience and tailored strategies.
free
Editorial
Mar 5
Gary S. Mintz, Carlos Collet
The study evaluated the association between intravascular imaging-guided percutaneous coronary intervention and outcomes in patients with acute coronary syndrome in Japan.
free
Original Research
Mar 4
Koki Takegawa, Yoshihiro Miyamoto, et al.
This nationwide study found that both OCT- and IVUS-guided percutaneous coronary intervention were associated with a lower risk of acute coronary syndrome recurrence compared to angiography-guided PCI in patients with acute coronary syndrome.
new issue
Mar 2
An expert review on non-invasive diagnosis of coronary dysfunction; excimer laser coronary atherectomy PCI; outcomes of intravascular imaging-guided PCI in ACS patients; absolute coronary flow after PCI; chronic limb-threatening ischaemia outcomes with drug-coated devices; percutaneous closure for transcarotid TAVI; and more
letter to the editor
Feb 27
Ali Husain, John G. Webb, et al.
This content discusses the potential benefits and considerations of the double-tap strategy in transcatheter heart valve implantation, suggesting it may be most beneficial in certain patient populations.
free
Flashlight
Mar 3
Radoslaw Parma, Damian Hudziak, et al.
This article describes the successful performance of a fully percutaneous transcarotid TAVI procedure using a collagen-based vascular closure device in a high-risk patient with severe aortic valve stenosis and multiple comorbidities.
letter to the editor
Feb 27
Matteo Sturla, Azeem Latib, et al.
The study by Husain et al. examined the need for routine post-dilatation in TAVI procedures, finding that a tailored approach may be reasonable with little impact on adverse events.
free
Editorial
Feb 26
Joanna J. Wykrzykowska, Robin P. Kraak
This article discusses the potential benefits of bioresorbable scaffolds (BRS) over permanent metallic stents in the treatment of coronary artery disease, and the need for future trials to determine the long-term efficacy of BRS versus drug-eluting balloons and optimal medical therapy.
free
Original Research
Feb 25
Pieter C. Smits, Robert-Jan van Geuns, et al.
The COMPARE-ABSORB trial found that bioresorbable vascular scaffolds (BVS) did not show superiority over everolimus-eluting stents (EES) in terms of target lesion failure at 7-year follow-up, despite a dedicated implantation protocol for BVS.
Editorial
Feb 24
Felice Gragnano, Paolo Calabrò
This study supports the use of early ticagrelor monotherapy after acute coronary syndromes, with the transition from dual antiplatelet therapy shown to be safe as early as a few weeks post-event.
free
Original Research
Feb 23
Jung-Hee Lee, Young Jin Youn, et al.
This study found that aspirin discontinuation within 1 month, followed by ticagrelor monotherapy, improved net clinical outcomes compared to 3-month discontinuation in patients with acute coronary syndrome undergoing percutaneous coronary intervention, primarily by reducing major bleeding without increasing ischemic risk.
State-of-the-Art
Feb 19
Asahi Oshima, Yoshinobu Onuma, et al.
This review summarizes the current evidence on lipid-lowering therapies, including statins, ezetimibe, bempedoic acid, and PCSK9 inhibitors, as well as the role of anti-inflammatory interventions in the management of atherosclerotic cardiovascular disease.
free
